Literature DB >> 28117207

COQ6 Mutations in Children With Steroid-Resistant Focal Segmental Glomerulosclerosis and Sensorineural Hearing Loss.

Eujin Park1, Yo Han Ahn1, Hee Gyung Kang2, Kee Hwan Yoo3, Nam Hee Won4, Kyoung Bun Lee5, Kyung Chul Moon6, Moon-Woo Seong7, Tae Rin Gwon8, Sung Sup Park7, Hae Il Cheong9.   

Abstract

The phenotypic combination of steroid-resistant focal segmental glomerulosclerosis (SR-FSGS) and sensorineural hearing loss has been mainly reported in patients with mitochondrial cytopathies, including primary coenzyme Q10 (CoQ10) deficiency. In this report of 10 children with SR-FSGS and sensorineural hearing loss, we found 6 patients with biallelic COQ6 mutations. Median age at the onset of nephrotic syndrome was 29 (range, 15-47) months. All patients progressed to end-stage renal disease within a median of 13 (range, 1-27) months after the onset. Kidney biopsy revealed abnormal mitochondrial proliferation in podocytes in all 6 patients. None of the 5 patients who underwent kidney transplantation developed recurrence of FSGS. Primary CoQ10 deficiency due to COQ6 mutations should be considered in children presenting with both SR-FSGS and sensorineural hearing loss. An early diagnosis of COQ6 mutations is essential because the condition is treatable when CoQ10 supplementation is started at the early stage. We recommend early kidney biopsy because detection of abnormal mitochondrial proliferation in podocytes might provide an earlier diagnostic clue.
Copyright © 2017 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  COQ6 mutation; Steroid-resistant focal segmental glomerulosclerosis (SR-FSGS); case report; children; coenzyme Q10 deficiency; end-stage renal disease (ESRD); kidney biopsy; mitochondrial cytopathy; mitochondrial proliferation in podocytes; pediatric; sensorineural hearing loss

Mesh:

Substances:

Year:  2017        PMID: 28117207     DOI: 10.1053/j.ajkd.2016.10.040

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  15 in total

1.  Deletion of the Mitochondrial Complex-IV Cofactor Heme A:Farnesyltransferase Causes Focal Segmental Glomerulosclerosis and Interferon Response.

Authors:  Jea-Hyun Baek; Ivan G Gomez; Yukihiro Wada; Allie Roach; Don Mahad; Jeremy S Duffield
Journal:  Am J Pathol       Date:  2018-09-28       Impact factor: 4.307

Review 2.  Treatment of nephrotic syndrome: going beyond immunosuppressive therapy.

Authors:  Jinghong Zhao; Zhihong Liu
Journal:  Pediatr Nephrol       Date:  2019-03-23       Impact factor: 3.714

3.  Clinical, Pathological, and Genetic Characteristics in Patients with Focal Segmental Glomerulosclerosis.

Authors:  China Nagano; Shigeo Hara; Norishige Yoshikawa; Asami Takeda; Yoshimitsu Gotoh; Riku Hamada; Kentaro Matsuoka; Masaki Yamamoto; Shuichiro Fujinaga; Koji Sakuraya; Koichi Kamei; Yuko Hamasaki; Hideyo Oguchi; Yoshinori Araki; Yayoi Ogawa; Takayuki Okamoto; Shuichi Ito; Seiji Tanaka; Hiroshi Kaito; Yuya Aoto; Shinya Ishiko; Rini Rossanti; Nana Sakakibara; Tomoko Horinouchi; Tomohiko Yamamura; Hiroaki Nagase; Kazumoto Iijima; Kandai Nozu
Journal:  Kidney360       Date:  2022-05-24

4.  Estimating the occurrence of primary ubiquinone deficiency by analysis of large-scale sequencing data.

Authors:  Bryan G Hughes; Paul M Harrison; Siegfried Hekimi
Journal:  Sci Rep       Date:  2017-12-18       Impact factor: 4.379

5.  MicroRNAs are inappropriate for characterising hearing impairment in mitochondrial disorders.

Authors:  Josef Finsterer; Sinda Zarrouk-Mahjoub
Journal:  Orphanet J Rare Dis       Date:  2018-05-31       Impact factor: 4.123

Review 6.  Application of next-generation sequencing technology to diagnosis and treatment of focal segmental glomerulosclerosis.

Authors:  Yutaka Harita
Journal:  Clin Exp Nephrol       Date:  2017-07-27       Impact factor: 2.801

7.  Genetic Study in Korean Pediatric Patients with Steroid-Resistant Nephrotic Syndrome or Focal Segmental Glomerulosclerosis.

Authors:  Eujin Park; Chung Lee; Nayoung K D Kim; Yo Han Ahn; Young Seo Park; Joo Hoon Lee; Seong Heon Kim; Min Hyun Cho; Heeyeon Cho; Kee Hwan Yoo; Jae Il Shin; Hee Gyung Kang; Il-Soo Ha; Woong-Yang Park; Hae Il Cheong
Journal:  J Clin Med       Date:  2020-06-26       Impact factor: 4.241

8.  New Mutation of Coenzyme Q10 Monooxygenase 6 Causing Podocyte Injury in a Focal Segmental Glomerulosclerosis Patient.

Authors:  Cheng-Cheng Song; Quan Hong; Xiao-Dong Geng; Xu Wang; Shu-Qiang Wang; Shao-Yuan Cui; Man-Di Guo; Ou Li; Guang-Yan Cai; Xiang-Mei Chen; Di Wu
Journal:  Chin Med J (Engl)       Date:  2018-11-20       Impact factor: 2.628

Review 9.  Primary coenzyme Q10 nephropathy, a potentially treatable form of steroid-resistant nephrotic syndrome.

Authors:  Weizhen Tan; Rannar Airik
Journal:  Pediatr Nephrol       Date:  2021-01-22       Impact factor: 3.714

10.  CoQ10 supplementation rescues nephrotic syndrome through normalization of H2S oxidation pathway.

Authors:  Giulio Kleiner; Emanuele Barca; Marcello Ziosi; Valentina Emmanuele; Yimeng Xu; Agustin Hidalgo-Gutierrez; Changhong Qiao; Saba Tadesse; Estela Area-Gomez; Luis C Lopez; Catarina M Quinzii
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-09-06       Impact factor: 6.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.